The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Laboratory Corporation of America Holdings

NYSE: LH
Last

(U.S.) $119.61

Today's change-0.21 -0.18%
Updated August 28 4:02 PM EDT. Delayed by at least 15 minutes.
 

Laboratory Corporation of America Holdings

NYSE: LH
Last

(U.S.) $119.61

Today's change-0.21 -0.18%
Updated August 28 4:02 PM EDT. Delayed by at least 15 minutes.

Laboratory Corporation of America Holdings down (U.S.)$0.21

Laboratory Corporation of America Holdings closed lower Friday, dropping (U.S.)$0.21 or 0.18% to (U.S.)$119.61. Shares have lost 0.57% over the last five days, but have gained 10.85% over the last year to date. This security has outperformed the S&P 500 by 13.89% during the last year.

Key company metrics

  • Open(U.S.) $119.63
  • Previous close(U.S.) $119.82
  • High(U.S.) $120.28
  • Low(U.S.) $118.86
  • Bid / Ask-- / --
  • YTD % change+10.85%
  • Volume717,592
  • Average volume (10-day)1,133,947
  • Average volume (1-month)1,022,088
  • Average volume (3-month)1,032,881
  • 52-week range(U.S.) $95.61 to (U.S.) $131.19
  • Beta0.75
  • Trailing P/E25.88×
  • P/E 1 year forward15.15×
  • Forward PEG1.35×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $4.62
Updated August 28 4:02 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+5.99%

Based on its net profit margin of 5.99%, Laboratory Corporation of America Holdings is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.71%Sector:HealthcareIndustry:Healthcare Facilities
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014
Revenue2,2691,7931,5131,552
Total other revenue--------
Total revenue2,2691,7931,5131,552
Gross profit775596547571
Total cost of revenue1,4951,197966981
Total operating expense1,9481,6631,2941,310
Selling / general / administrative392415310306
Research & development--------
Depreciation / amortization47311518
Interest expense (income), net operating--------
Unusual expense (income)141926
Other operating expenses, total--------
Operating income321130219241
Interest income (expense), net non-operating-58-104-32-26
Gain (loss) on sale of assets--------
Other--------
Income before tax26430188219
Income after tax1691120138
Income tax, total96296882
Net income1681120137
Total adjustments to net income--------
Net income before extra. items1681120137
Minority interest0000
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items1681120137
Inc. avail. to common incl. extra. items1681120137
Diluted net income1681120137
Dilution adjustment0--0--
Diluted weighted average shares103948687
Diluted EPS excluding extraordinary itemsvalue per share1.640.011.391.59
Dividends per sharevalue per share0.000.00--0.00
Diluted normalized EPSvalue per share1.730.141.401.63